BioRestorative amends 8-K to clarify auditor change, audit committee probe scope
BRTX•Audit committee investigation remains ongoing
An audit committee investigation into the product suspension remained ongoing, with no new material findings reported to date.
Amended 8-K clarifies auditor change disclosures
BioRestorative filed an amended 8-K to clarify disclosures on its auditor change and related reportable-event discussions with former auditor CBIZ.
New auditor engaged for upcoming and prior-year audits
Bush & Associates CPA was engaged to audit fiscal 2026 financials and re-audit fiscal 2025 and 2024.
CBIZ flagged potential reportable event tied to product suspensions
CBIZ flagged a potential reportable event tied to the suspension of ExoCR and BioX product lines, citing possible implications for prior financial statements.
The company said CBIZ had not concluded its prior audit reports or financial statements were unreliable, nor advised investors to stop relying on them.
